Nazca Capital's exclusive talks to acquire Aldous Bio could reshape Spain's nutraceutical M&A marketExecutive summary: Nazca Capital is in exclusive negotiations to buy Aldous Bio, a Spanish supplement manufacturer. The potential acquisition could signal heightened M&A activity in the Spanish nutraceutical market and impact valuation of similar firms. Nazca Capital and Aldous Bio's shareholders. An agreement could be announced within weeks, pending due diligence and possible regulatory review.Nazca Capital, a Spanish private‑equity firm, is in exclusive negotiations to purchase Aldous Bio, a manufacturer of nutritional supplements. The deal, if completed, would mark a notable transaction in the Spanish health‑food sector. Neither party has disclosed financial terms, and the timeline hinges on reaching agreement within weeks. The transaction reflects ongoing investor interest in consumer‑focused biotech assets.Connected developmentsFox‑Roku deal shows media shift to controlAMD approaches $900 billion valuationFramework agreement on Iran nuclear dealOpen the full case file on Beyond →
Social Pulse
AI estimate · not scraped